F000 contributes to the whole map as a level (F000/V). If calculated with a only difference of with or w/o F000, should the sigma levels of the two maps be the same? That is why we could rely on maps for modeling that are calculated w/o F000 item. Lijun
On Nov 28, 2012, at 2:30 PM, Pavel Afonine wrote: > For map in e-/A^3 units to make sense one needs to obtain F000, which may be > more tricky than one may think. Interesting, how Coot does this given just a > set of Fourier map coefficients? > > Pavel > > On Wed, Nov 28, 2012 at 12:21 PM, Greg Costakes <gcost...@purdue.edu> wrote: > You stated that the map is set to 3 sigma, but what is the e-/A^3? In Coot I > often find that my fo-fc map needs to be maxed out (max sigma) in order to > get to an acceptable e-/A^3. It is possible that your fo-fc map at 3 sigma > has an e-/A^3 of 0.04 or something low like that. > > ------------------------------------------------------------------------------- > Greg Costakes > PhD Candidate > Department of Structural Biology > Purdue University > Hockmeyer Hall, Room 320 > 240 S. Martin Jischke Drive, West Lafayette, IN 47907 > > -------------------------------------------------------------------------------- > > > From: "Jon Read" <jon.r...@astrazeneca.com> > To: CCP4BB@JISCMAIL.AC.UK > Sent: Wednesday, November 28, 2012 10:48:04 AM > Subject: [ccp4bb] Strange density > > > > Anyone see anything like this before? The data is 1.7Angstrom data with good > statistics. The picture shows the solid FoFc density contoured at 3 Sigma in > light brown and -3 Sigma in purple. The density is odd as it appears to be > bound to a peptide carbonyl with no other obvious interactions with the > protein. There is a characteristic tail at one end. > > > > > > > > > > AstraZeneca UK Limited is a company incorporated in England and Wales with > registered number: 03674842 and a registered office at 2 Kingdom Street, > London, W2 6BD. > > > Confidentiality Notice: This message is private and may contain confidential, > proprietary and legally privileged information. If you have received this > message in error, please notify us and remove it from your system and note > that you must not copy, distribute or take any action in reliance on it. Any > unauthorised use or disclosure of the contents of this message is not > permitted and may be unlawful. > > > Disclaimer: Email messages may be subject to delays, interception, > non-delivery and unauthorised alterations. Therefore, information expressed > in this message is not given or endorsed by AstraZeneca UK Limited unless > otherwise notified by an authorised representative independent of this > message. No contractual relationship is created by this message by any person > unless specifically indicated by agreement in writing other than email. > > > Monitoring: AstraZeneca UK Limited may monitor email traffic data and content > for the purposes of the prevention and detection of crime, ensuring the > security of our computer systems and checking compliance with our Code of > Conduct and policies. > > > > > > > > > > > > > > >
